Today: 7 February 2026
Subscribe
Browse Category

Pharma News News 6 January 2026 - 9 January 2026

Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

NEW YORK, Jan 9, 2026, 10:58 (EST) CICC initiated coverage on Novo Nordisk’s U.S.-listed American depositary receipt (ADR) — a U.S.-traded certificate that represents shares in a foreign company — with an outperform rating and a $73.50 price target, a Finwire report carried by MarketScreener showed on Friday. Novo’s Copenhagen-listed stock was up about 3%. (MarketScreener) The call lands as Novo tries to widen access to Wegovy in pill form, a key test for the maker of Ozempic after profit warnings and sliding shares last year. Investors have watched Eli Lilly pull ahead in the U.S. obesity market, and any
9 January 2026
····
Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

PARIS, Jan 8, 2026, 20:02 (CET) — Market closed Shares in French biotech Abivax SA (ABVX.PA) closed down 9.49% at 99.20 euros on Thursday, after swinging between 112.40 euros at the open and a low of 94.20 euros. The stock slipped back under the 100-euro mark, with volume at about 246,000 shares, after a 6% rise the day before. MarketScreener The selling pressure comes as investors look ahead to key readouts for obefazimod, Abivax’s lead drug candidate for ulcerative colitis, a chronic inflammatory bowel disease. Abivax has told investors topline results from its Phase 3 maintenance study are expected in
8 January 2026
·····
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

New York, January 8, 2026, 13:12 ET — Regular session AbbVie Inc shares fell on Thursday after the drugmaker denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge that will dent its 2025 profit outlook. AbbVie stock (ABBV) was down 3.7% at $224.84 at 1:12 p.m. ET, after swinging between $231.93 and $223.84. The decline takes steam out of a rally sparked by a Wall Street Journal report that AbbVie was in advanced talks to buy Revolution Medicines. AbbVie told Reuters it “is not in discussions with Revolution Medicines,” and also trimmed its 2025 profit forecast
8 January 2026
······
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

New York, Jan 8, 2026, 08:36 EST — Premarket Eli Lilly shares were up 4.1% at $1,108.09 in premarket trade on Thursday after the drugmaker agreed to buy autoimmune-focused biotech Ventyx Biosciences for $1.2 billion in cash. The deal adds oral drugs for inflammatory diseases and a mid-stage program tied to a cardiovascular condition linked to obesity. “We like that Lilly is taking chances on potentially transformative opportunities,” Cantor Fitzgerald analyst Carter Gould said. Reuters The move matters because Lilly’s stock has become a proxy for the weight-loss boom, and investors are now looking for what comes after the first
8 January 2026
····
Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

New York, January 7, 2026, 20:54 (EST) — Market closed Bristol Myers Squibb shares rose 4.2% to $56.72 on Wednesday after UBS upgraded the drugmaker to buy and lifted its price target to $65 from $46. TipRanks The call matters now because big drugmakers are trying to convince investors they can bridge the next few years of patent losses without giving up growth later. Bristol Myers has been a litmus test for that trade: steady cash flows, but an earnings gap investors do not want to underwrite blindly. UBS analyst Michael Yee said the stock’s “risk/reward ratio” is “skewed… to
8 January 2026
·····
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

NEW YORK, January 7, 2026, 19:17 EST — After-hours Amgen shares (AMGN.O) rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price target, saying it sees “upside from EPS and pipeline.” Why this matters now is simple: investors are testing whether Amgen’s next growth bets can outrun erosion in older blockbusters. The FDA on Tuesday approved Amneal’s denosumab biosimilars — near-copies of complex biologic drugs that typically enter at lower prices — as alternatives to Amgen’s Prolia and Xgeva, products with about
8 January 2026
······
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

New York, Jan 7, 2026, 16:14 (EST) AbbVie (ABBV.N) is in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-talks-buy-biotech-revolution-medicines-wsj-reports-2026-01-07/ For AbbVie, a takeover would also sharpen its push to add new growth drivers as its former blockbuster Humira faces steeper competition after patent protection ended. It would put AbbVie deeper into oncology at a time when big drugmakers are still paying up for late-stage cancer assets. https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1 The Journal did not
7 January 2026
····
Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

New York, Jan 7, 2026, 12:57 (EST) — Regular session Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE. The spark this week came from Arrowhead Pharmaceuticals, which on Tuesday posted interim results from its obesity candidates aimed at INHBE or its receptor, ALK7. Arrowhead said its ARO-INHBE nearly doubled weight loss when paired with Eli Lilly’s tirzepatide, and drove what an outside expert called “dramatic and rapid reductions in visceral fat,” the fat that builds
7 January 2026
·····
Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

New York, January 7, 2026, 11:41 EST — Regular session. Eli Lilly and Company shares were up 3.3% at $1,099.44 in late morning trade, pushing back toward the $1,100 level as investors cheered fresh deal chatter around the drugmaker’s pipeline. (https://www.reuters.com/markets/companies/LLY.N/) The lift matters now because the market is watching how Lilly defends its growth run while competitors push pill versions of obesity drugs and pricing stays in flux. Investors have rewarded companies that can keep adding late-stage shots on goal without derailing margins. The Wall Street Journal reported Lilly is in advanced talks to buy Ventyx Biosciences for more
7 January 2026
····
Liquidia stock slides after Needham swaps LQDA off its 2026 Conviction List

Liquidia stock slides after Needham swaps LQDA off its 2026 Conviction List

New York, Jan 6, 2026, 15:31 EST — Regular session Shares of Liquidia Corp (LQDA) fell 6.2% to $30.17 in afternoon trading on Tuesday after Needham removed the stock from its 2026 “Conviction List,” a report said. The shares hit a session low of $29.47, down from Monday’s close of $32.15. The decline stood out against a firmer biotech backdrop. The SPDR S&P Biotech ETF was up about 1.1% and the iShares Nasdaq Biotechnology ETF gained about 2.0%. For Liquidia, sentiment often tracks expectations for Yutrepia, its inhaled treprostinil powder used to treat pulmonary arterial hypertension (PAH), a form of
6 January 2026
·······
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

NEW YORK, Jan 6, 2026, 08:19 EST — Premarket Cyclerion Therapeutics Inc shares jumped about 46% to around $2.01 in premarket trading on Tuesday after the company announced an expanded strategic collaboration with Medsteer to advance its closed-loop anesthetic platform, CYC-126. Benzinga The move matters because Cyclerion is trying to pair an anesthetic-based approach with a device-and-software system that adjusts dosing using real-time feedback — a setup that can add complexity but also sharpen execution in early trials. For small biotechs, clearer milestones can quickly reset expectations for funding and timelines. Cyclerion said the agreement is exclusive and includes an
6 January 2026
·····
GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

London, January 6, 2026, 09:03 GMT — Regular session GSK plc shares rose nearly 1% in early London trade on Tuesday after the drugmaker said Japan had approved its bronchial asthma treatment Exdensur. Shares were up 0.96% at 1,838 pence by 0830 GMT. sharecast.com The decision lands as investors weigh whether GSK’s next wave of respiratory launches can broaden growth beyond its established portfolio. Long-acting medicines that cut the number of injections can be a commercial lever, but they also have to win reimbursement and persuade patients and doctors to switch. The Japan approval followed a separate regulatory win in
6 January 2026
···
1 2 3 4 5 … 11

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop